US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Denali Therapeutics Inc. - Common Stock
(NQ:
DNLI
)
20.00
-0.53 (-2.58%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Denali Therapeutics Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 10, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 09, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Royalty Pharma plc
Via
GlobeNewswire
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 04, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Board and Executive Leadership Updates
November 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
FDA Delays Decision Date For Denali Therapeutics' Lead Drug Candidate
↗
October 14, 2025
FDA extends review of Denali Therapeutics' tividenofusp alfa for Hunter syndrome to April 2026; analysts remain confident in its approval prospects.
Via
Benzinga
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 13, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 11, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 07, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
What Happened To Denali Therapeutics Stock Wednesday?
↗
April 02, 2025
Denali Therapeutics, Inc. (NASDAQ:DNLI) shares traded higher on Wednesday after the company initiated its biologics license application (BLA) for the accelerated approval of Tividenofusp Alfa for the...
Via
Benzinga
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 02, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Despite Trial Setback
↗
March 06, 2025
Denali Therapeutics' ALS drug DNL343 failed to show efficacy, leading to the discontinuation of the trial extension. Analysts now focus on its Hunter syndrome drug.
Via
Benzinga
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 27, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 30, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Why Is Denali Therapeutics Stock Trading Higher On Wednesday?
↗
January 15, 2025
Denali Therapeutics showcases its BBB platform at J.P. Morgan Conference, highlighting DNL310's Hunter syndrome progress and plans for commercialization.
Via
Benzinga
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 13, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 08, 2025
Denali expects to submit a Biologics License Application for tividenofusp alfa in early 2025 for regulatory review under the accelerated approval pathway
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
↗
January 07, 2025
Denali's DNL343 missed efficacy goals in the HEALEY ALS trial but was well-tolerated. Analysts await detailed biomarker data and subgroup analyses in 2025.
Via
Benzinga
Denali Therapeutics Ratchets Up Losses On Misstep In ALS Treatment. Why The Game Isn't Over Yet.
↗
January 07, 2025
One analyst says the six-month study was too short and the benefits could appear over time.
Via
Investor's Business Daily
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
January 06, 2025
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
↗
January 03, 2025
William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.
Via
Benzinga
This Denali Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Friday
↗
January 03, 2025
Via
Benzinga
Denali Therapeutics Announces First Participant Dosed in Phase 2a Study of LRRK2 Inhibitor, BIIB122, in LRRK2-Associated Parkinson’s Disease
December 05, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
November 06, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Stock Is Sliding After The Bell: Here's Why
↗
October 10, 2024
Denali Therapeutics shares are moving lower in Thursday's after-hours session after the company announced that its Phase 2 study of oditrasertib was discontinued.
Via
Benzinga
A Biotech Breakout Will Be Led By Small Caps
↗
September 23, 2024
It’s hard to focus on biotech stocks right now because there are many distractions. The Fed and the rate cuts, AI and semiconductor stocks and geopolitical turmoil seemingly worse than ever.
Via
Talk Markets
Topics
Artificial Intelligence
Economy
Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)
September 03, 2024
From
Denali Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
Next >
